468 related articles for article (PubMed ID: 29320431)
1. Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.
Wdowiak K; Francuz T; Gallego-Colon E; Ruiz-Agamez N; Kubeczko M; Grochoła I; Wojnar J
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29320431
[TBL] [Abstract][Full Text] [Related]
2. Low or No Inhibitory Potency of the Canonical Galectin Carbohydrate-binding Site by Pectins and Galactomannans.
Stegmayr J; Lepur A; Kahl-Knutson B; Aguilar-Moncayo M; Klyosov AA; Field RA; Oredsson S; Nilsson UJ; Leffler H
J Biol Chem; 2016 Jun; 291(25):13318-34. PubMed ID: 27129206
[TBL] [Abstract][Full Text] [Related]
3. Galectin binding to cells and glycoproteins with genetically modified glycosylation reveals galectin-glycan specificities in a natural context.
Nielsen MI; Stegmayr J; Grant OC; Yang Z; Nilsson UJ; Boos I; Carlsson MC; Woods RJ; Unverzagt C; Leffler H; Wandall HH
J Biol Chem; 2018 Dec; 293(52):20249-20262. PubMed ID: 30385505
[TBL] [Abstract][Full Text] [Related]
4. Non-carbohydrate strategies to inhibit lectin proteins with special emphasis on galectins.
Sethi A; Sanam S; Alvala M
Eur J Med Chem; 2021 Oct; 222():113561. PubMed ID: 34146913
[TBL] [Abstract][Full Text] [Related]
5. Glycans and galectins in prostate cancer biology, angiogenesis and metastasis.
Compagno D; Gentilini LD; Jaworski FM; Pérez IG; Contrufo G; Laderach DJ
Glycobiology; 2014 Oct; 24(10):899-906. PubMed ID: 24939371
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of galectins with small molecules.
Oberg CT; Leffler H; Nilsson UJ
Chimia (Aarau); 2011; 65(1-2):18-23. PubMed ID: 21469439
[TBL] [Abstract][Full Text] [Related]
7. Complex N-glycans are the major ligands for galectin-1, -3, and -8 on Chinese hamster ovary cells.
Patnaik SK; Potvin B; Carlsson S; Sturm D; Leffler H; Stanley P
Glycobiology; 2006 Apr; 16(4):305-17. PubMed ID: 16319083
[TBL] [Abstract][Full Text] [Related]
8. Role of Galectins in Tumors and in Clinical Immunotherapy.
Chou FC; Chen HY; Kuo CC; Sytwu HK
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389859
[TBL] [Abstract][Full Text] [Related]
9. Generation and Use of Recombinant Galectins.
Wu SC; Paul A; Ho A; Patel KR; Allen JWL; Verkerke H; Arthur CM; Stowell SR
Curr Protoc; 2021 Mar; 1(3):e63. PubMed ID: 33656274
[TBL] [Abstract][Full Text] [Related]
10. Galectin-7 in Epithelial Homeostasis and Carcinomas.
Advedissian T; Deshayes F; Viguier M
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29257082
[TBL] [Abstract][Full Text] [Related]
11. Targeting galectin-driven regulatory circuits in cancer and fibrosis.
Mariño KV; Cagnoni AJ; Croci DO; Rabinovich GA
Nat Rev Drug Discov; 2023 Apr; 22(4):295-316. PubMed ID: 36759557
[TBL] [Abstract][Full Text] [Related]
12. Inhibition mechanism of human galectin-7 by a novel galactose-benzylphosphate inhibitor.
Masuyer G; Jabeen T; Öberg CT; Leffler H; Nilsson UJ; Acharya KR
FEBS J; 2012 Jan; 279(2):193-202. PubMed ID: 22059385
[TBL] [Abstract][Full Text] [Related]
13. [Galectins in hematological malignancies--role, functions and potential therapeutic targets].
Wdowiak K; Spychałowicz W; Fajkis M; Wojnar J
Postepy Hig Med Dosw (Online); 2016 Feb; 70():95-103. PubMed ID: 26943306
[TBL] [Abstract][Full Text] [Related]
14. Enzymatic synthesis of non-natural trisaccharides and galactosides; Insights of their interaction with galectins as a function of their structure.
Porciúncula González C; Cagnoni AJ; Mariño KV; Fontana C; Saenz-Méndez P; Irazoqui G; Giacomini C
Carbohydr Res; 2019 Jan; 472():1-15. PubMed ID: 30428394
[TBL] [Abstract][Full Text] [Related]
15. Anti-galectin compounds as potential anti-cancer drugs.
Ingrassia L; Camby I; Lefranc F; Mathieu V; Nshimyumukiza P; Darro F; Kiss R
Curr Med Chem; 2006; 13(29):3513-27. PubMed ID: 17168720
[TBL] [Abstract][Full Text] [Related]
16. Targeting the CRD F-face of Human Galectin-3 and Allosterically Modulating Glycan Binding by Angiostatic PTX008 and a Structurally Optimized Derivative.
Miller MC; Zheng Y; Suylen D; Ippel H; Cañada FJ; Berbís MA; Jiménez-Barbero J; Tai G; Gabius HJ; Mayo KH
ChemMedChem; 2021 Feb; 16(4):713-723. PubMed ID: 33156953
[TBL] [Abstract][Full Text] [Related]
17. Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy.
Liu D; Zhu H; Li C
Biomark Res; 2023 Feb; 11(1):22. PubMed ID: 36814341
[TBL] [Abstract][Full Text] [Related]
18. Regioselective 3-O-Substitution of Unprotected Thiodigalactosides: Direct Route to Galectin Inhibitors.
Vašíček T; Spiwok V; Červený J; Petrásková L; Bumba L; Vrbata D; Pelantová H; Křen V; Bojarová P
Chemistry; 2020 Aug; 26(43):9620-9631. PubMed ID: 32368810
[TBL] [Abstract][Full Text] [Related]
19. Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin.
Vladoiu MC; Labrie M; Létourneau M; Egesborg P; Gagné D; Billard É; Grosset AA; Doucet N; Chatenet D; St-Pierre Y
Oncotarget; 2015 Dec; 6(38):40970-80. PubMed ID: 26543238
[TBL] [Abstract][Full Text] [Related]
20. Unraveling galectin-1 as a novel therapeutic target for cancer.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
